N-methyl-4-piperidinone O-methyloxime | 137239-20-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-methyl-4-piperidinone O-methyloxime
• 英文别名: N-methoxy-1-methylpiperidin-4-imine
• CAS: 137239-20-4
• 化学式: C₇H₁₄N₂O
• mdl: MFCD25958594
• 分子量: 142.201
• InChiKey: WVMYKOKEHJOIDX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  24.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-甲基-4-哌啶酮 、 甲氧基胺盐酸盐 以 甲醇 为溶剂， 反应 18.0h， 生成 N-methyl-4-piperidinone O-methyloxime
  参考文献：
  名称：

  Synthesis and Pharmacological Characterization of O-Alkynyloximes of Tropinone and N-Methylpiperidinone as Muscarinic Agonists

  摘要：

  A number of O-alkynyloximes of tropinone and N-methyl-4-piperidinone have been synthesized and evaluated for muscarinic activity. The affinities of these oximes were tested in homogenates of cerebral cortex, heart, and submandibulary glands from rats using [H-3]pirenzepine and [H-3]- N-methylscopolamine as radioligands. The oximes bind to the cortical muscarinic receptors with pK(i) values varying from 3 to 7. Higher binding affinities were observed for the O-alkynyl tropinone oximes than the corresponding piperidinone analogues. Binding to the muscarinic sites in the heart and submandibulary glands was also observed but with lower affinities. Good M-1 subtype selectivity (10-fold or greater) was observed with some oximes (26a, 28a, 32a) at the cortical sites. These oximes also attenuated scopolamine-induced impairment of the water mask task in mice. Functional assays for Ma activity on the rat aorta showed that all oximes possessed M-3 agonist action but M-2 agonist activity was not observed at the endothelium-denuded rabbit aorta. Analysis of the quantitative structure-activity relationship (QSAR) indicated that the Connolly surface area is an important determinant of activity, accounting for 70% of the variation in cortical binding affinity among the oximes.

  DOI：

  10.1021/jm9708588

文献信息

• [EN] CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT<br/>[FR] DÉRIVÉ DE CYCLOHEXÈNE, SON PROCÉDÉ DE PRÉPARATION ET COMPOSITION PHARMACEUTIQUE POUR PRÉVENIR OU TRAITER UNE MALADIE MÉTABOLIQUE, CONTENANT LEDIT DÉRIVÉ COMME PRINCIPE ACTIF
  申请人：HYUNDAI PHARM CO LTD

  公开号：WO2017078352A1

  公开（公告）日：2017-05-11

  The present invention relates to: a cyclohexene derivative; a preparation method thereof; and a pharmaceutical composition for preventing or treating metabolic disease comprising the same as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (cAMP) by activating G protein-coupled receptor 119 (GPR-119) and simultaneously exhibits weight loss and hypoglycemic effects by inducing the release of glucagon-like peptide-1 (GLP-1), which is a neuroendocrine protein, and thus can be useful as a pharmaceutical composition for preventing or treating metabolic diseases such as obesity, type 1 diabetes, type 2 diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia and syndrome X.

  本发明涉及：一种环己烯衍生物；其制备方法；以及一种包含该衍生物作为活性成分的用于预防或治疗代谢疾病的药物组合物。根据本发明的环己烯衍生物通过激活G蛋白偶联受体119（GPR-119）增加了细胞内环状腺苷一磷酸（cAMP）的活性，并通过诱导释放神经内分泌蛋白胰高血糖素样肽-1（GLP-1），同时表现出减肥和降糖效果，因此可作为预防或治疗诸如肥胖、1型糖尿病、2型糖尿病、葡萄糖耐量不足、胰岛素抵抗、高血糖、高脂血症、高甘油三酯血症、高胆固醇血症、血脂异常和综合征X等代谢疾病的药物组合物。
• NOVEL AZABICYCLOHEXANES
  申请人：Jain Rajseh

  公开号：US20120165320A1

  公开（公告）日：2012-06-28

  The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.

  本发明涉及公式I的新化合物，其药学上可接受的衍生物，互变异构体，立体异构体包括R和S异构体，多晶型，前药，代谢物，盐或溶剂的形式。该发明还涉及用于合成公式I的新化合物，其药学上可接受的衍生物，互变异构体，立体异构体，多晶型，前药，代谢物，盐或溶剂的过程。
• TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF
  申请人：Namane Claudie

  公开号：US20120135958A1

  公开（公告）日：2012-05-31

  The invention relates to compounds of formula (I), where: A is a bond, an oxygen, or an —CH 2 — group; Ar 1 is a phenyl or heteroaryl group; Ar 2 is a phenyl, heteroaryl, or heterocycloalkyl group; R 1a,b,c and R 2a,b,c are hydrogen or halogen, or an alkyl, cycloalkyl, or lkyl-cycloalkyl group optionally, substituted by one or more halogen atoms, or a —OR 5 (hydroxy or alkoxy), hydroxy-alkyl, alkoxy-alkyl, alkoxy-alkoxy, halogenoalkyl, —O-halogenoalkyl, oxo, —CO-alkyl, —CO-alkyl-NR 6 R 7 , —CO-halogenoalkyl, —COOR 5 , alkyl-COOR 5 , —O-alkyl-COOR 5 , —SO 2 -alkyl, —SO 2 -cycloalkyl, —SO 2 -alkyl-cycloalkyl, —SO 2 -alkyl-OR 5 , —SO 2 -alkyl-COOR 5 , —SO 2 -alkyl-NR 6 R 7 , —SO 2 -halogenoalkyl, alkyl-SO 2 -alkyl, —SO 2 —NR 6 R 7 , —SO 2 -alkyl-O-alkyl-OR 5 , —CONR 6 R 7 , -alkyl-CONR 6 R 7 , or -alkyl-NR 6 R 7 group, or further R 1a , R 1b , and R 1c are bonded to R 2a , R 2b , R 2c , respectively, and to the carbon atom having same, and are -alkyl-O—; R 3 is a hydrogen atom or an alkyl group; R 4 is a hydrogen or halogen atom or a cyano, —OR 5 , hydroxyalkyl, —COOR 5 , —NR 6 R 7 , ONR 6 R 7 , —SO 2 -alkyl, SO 2 —NR 6 R 7 , —NR 6 —COOR 5 , —NR 6 —COR 5 , or —CO—NR 6 -alkyl-OR 5 group; R 5 , R 6 , and R 7 are a hydrogen, or an alkyl or alkyl-phenyl group; and R 8 is an alkyl, alkyl-Si(alkyl) 3 , —SO 2 -alkyl-Si(alkyl) 3 , phenyl, alkoxy-imino group, or alkyl-cycloalkyl group optionally substituted by one or more halogen atoms or one or more hydroxyl or hydroxyl-alkyl groups; or R 8 and R 9 , together with the carbon atoms to which they are bonded, form a cycloalkyl group optionally substituted by one or more halogen atoms or one or more carboxy groups; and R 9 is a hydrogen atom or an alkyl group; with the proviso that, when R 8 is an alkyl group, it is bonded onto the Ar 2 silicon atom. The invention also relates to a method for preparing same and to the therapeutic use thereof.

  该发明涉及公式(I)的化合物，其中：A是一个键，一个氧或一个—CH2—基团；Ar1是一个苯基或杂环芳基；Ar2是一个苯基，杂环芳基或杂环烷基基团；R1a，b，c和R2a，b，c是氢或卤素，或一个烷基，环烷基或烷基-环烷基基团，可以被一个或多个卤素原子取代，或一个—OR5（羟基或烷氧基），羟基-烷基，烷氧基-烷基，烷氧基-烷氧基，卤代烷基，—O-卤代烷基，酮基，—CO-烷基，—CO-烷基-NR6R7，—CO-卤代烷基，—COOR5，烷基-COOR5，—O-烷基-COOR5，—SO2-烷基，—SO2-环烷基，—SO2-烷基-环烷基，—SO2-烷基-OR5，—SO2-烷基-COOR5，—SO2-烷基-NR6R7，—SO2-卤代烷基，烷基-SO2-烷基，—SO2-NR6R7，—SO2-烷基-O-烷基-OR5，—CONR6R7，-烷基-CONR6R7，或-烷基-NR6R7基团，或进一步的R1a，R1b和R1c与R2a，R2b和R2c分别结合，并与具有相同的碳原子结合，并且是-烷基-O-；R3是氢原子或烷基基团；R4是氢或卤素原子或氰基，—OR5，羟基烷基，—COOR5，—NR6R7，ONR6R7，—SO2-烷基，SO2-NR6R7，—NR6—COOR5，—NR6—COR5，或—CO—NR6-烷基-OR5基团；R5，R6和R7是氢，或烷基或烷基-苯基基团；R8是一个烷基，烷基-Si（烷基）3，—SO2-烷基-Si（烷基）3，苯基，烷氧基-亚胺基团，或烷基-环烷基基团，可以被一个或多个卤素原子或一个或多个羟基或羟基-烷基基团取代；或R8和R9，与它们结合的碳原子一起，形成一个可以被一个或多个卤素原子或一个或多个羧基取代的环烷基基团；R9是氢原子或烷基基团；但是，当R8是烷基基团时，它与Ar2硅原子结合。该发明还涉及制备该化合物的方法和其治疗用途。
• CYCLIC AMINE COMPOUND AND PEST CONTROL AGENT
  申请人：Nippon Soda Co., Ltd.

  公开号：US20200163336A1

  公开（公告）日：2020-05-28

  A pest control agent according to the present invention contains a compound of formula (I) (in the formula, Ar represents a substituted or unsubstituted C6-10 aryl group, R 1 represents a cyano group or a substituted or unsubstituted thiocarbamoyl group, R 2 represents a hydrogen atom, a halogeno group, a substituted or unsubstituted C1-6 alkyl group, a hydroxyl group, or a substituted or unsubstituted C1-6 alkoxy group, R 3 represents a hydrogen atom, a halogeno group, a substituted or unsubstituted C1-6 alkyl group, or the like, and Q represents a cyclic amino group) or a salt thereof.

  根据本发明，一种害虫控制剂包含化合物的公式（I）（在该式中，Ar代表取代或未取代的C6-10芳基，R1代表氰基或取代或未取代的硫代氨基基团，R2代表氢原子、卤素基团、取代或未取代的C1-6烷基基团、羟基或取代或未取代的C1-6烷氧基团，R3代表氢原子、卤素基团、取代或未取代的C1-6烷基基团等，Q代表环氨基基团）或其盐。
• Oxime substituted imidazoquinolines
  申请人：Kshirsagar A. Tushar

  公开号：US20070066639A1

  公开（公告）日：2007-03-22

  Imidazo-containing compounds (e.g., imidazoquinolines, imidazonaphthyridines, and imidazopyridines) with an oxime substituent at the 1-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

  本发明涉及含咪唑基的化合物（例如咪唑喹啉，咪唑萘啶和咪唑吡啶），其在1位上具有肟基取代基，包含这些化合物的药物组合物，中间体以及这些化合物作为免疫调节剂的使用方法，用于诱导动物细胞因子生物合成和治疗包括病毒和肿瘤疾病在内的疾病。